Patents by Inventor Paul Maes

Paul Maes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified-release formulations of a bupropion salt
    Patent number: 7884136
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: February 8, 2011
    Assignee: Biovail Laboratories International S.R.L.
    Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Stefano Turchetta, Graham Jackson, Pietro Massardo, Mohammad Ashty Saleh
  • BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS
    Publication number: 20100255094
    Abstract: Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
    Type: Application
    Filed: October 28, 2008
    Publication date: October 7, 2010
    Applicant: BIOVAIL LABORATORIES INTERNATIONAL SRL
    Inventors: Graham Jackson, Werner Oberegger, Paul Maes, Mohammad Ashty Saleh
  • MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT
    Publication number: 20100222435
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Application
    Filed: June 27, 2006
    Publication date: September 2, 2010
    Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.
    Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Stefano Turchetta, Graham Jackson, Pietro Massardo, Mohammad Ashty Saleh
  • Controlled release dosage forms
    Patent number: 7780987
    Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: August 24, 2010
    Assignee: Biovail Laboratories International SRL
    Inventors: Fang Zhou, Paul Maes
  • Modified release formulations of a bupropion salt
    Patent number: 7662407
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: February 16, 2010
    Assignee: Biovail Laboratories International S.R.L.
    Inventors: Werner Oberegger, Paul Maes, Graham Jackson, Mohammad Ashty Saleh
  • Modified release formulations of a bupropion salt
    Patent number: 7649019
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: January 19, 2010
    Assignee: Biovail Laboratories International S.R.L.
    Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Graham Jackson, Mohammad Ashty Saleh
  • Bupropion hydrobromide and therapeutic applications
    Patent number: 7645802
    Abstract: Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: January 12, 2010
    Assignee: Biovail Laboratories International SRL.
    Inventors: Werner Oberegger, Paul Maes, Mohammad Ashty Saleh, Graham Jackson
  • Modified release formulations of a bupropion salt
    Patent number: 7645901
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: January 12, 2010
    Assignee: Biovail Laboratories International S.R.L.
    Inventors: Werner Oberegger, Paul Maes, Stefano Turchetta, Pietro Massardo, Mohammad Ashty Saleh
  • MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE
    Publication number: 20090269402
    Abstract: The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially, surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.
    Type: Application
    Filed: April 17, 2009
    Publication date: October 29, 2009
    Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.
    Inventors: Fang ZHOU, Werner Oberegger, Paul Maes
  • MODIFIED RELEASE COMPOSITION OF AT LEAST ONE FORM OF VENLAFAXINE
    Publication number: 20090258067
    Abstract: The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.
    Type: Application
    Filed: April 17, 2009
    Publication date: October 15, 2009
    Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L
    Inventors: Fang ZHOU, Paul Maes, Steven Frisbee
  • Modified release formulations of a bupropion salt
    Patent number: 7585897
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: September 8, 2009
    Assignee: Biovail Laboratories International S.r.l.
    Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Graham Jackson, Mohammad Ashty Saleh
  • Modified release formulations of a bupropion salt
    Patent number: 7579380
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: August 25, 2009
    Assignee: Biovail Laboratories International S.R.L.
    Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Stefano Turchetta, Graham Jackson, Pietro Massardo, Mohammad Ashty Saleh
  • Modified release formulations of a bupropion salt
    Patent number: 7572935
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: August 11, 2009
    Assignee: Biovail Laboratories International S.R.L.
    Inventors: Werner Oberegger, Paul Maes, Stefano Turchetta, Pietro Massardo, Mohammad Ashty Saleh
  • Modified release formulations of a bupropion salt
    Patent number: 7569610
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: August 4, 2009
    Assignee: Biovail Laboratories International SRL
    Inventors: Werner Oberegger, Paul Maes, Mohammad Ashty Saleh
  • Modified release formulations of a bupropion salt
    Patent number: 7569611
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: August 4, 2009
    Assignee: Biovail Laboratories International SRL.
    Inventors: Werner Oberegger, Paul Maes, Mohammad Ashty Saleh
  • Modified release formulations of a bupropion salt
    Patent number: 7563823
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: July 21, 2009
    Assignee: Biovail Laboratories International SRL.
    Inventors: Werner Oberegger, Paul Maes, Graham Jackson, Mohammad Ashty Saleh
  • Modified release formulations of a bupropion salt
    Patent number: 7553992
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: June 30, 2009
    Assignee: Biovail Laboratories International S.R.L.
    Inventors: Werner Oberegger, Paul Maes, Stefano Turchetta, Pietro Massardo, Mohammad Ashty Saleh
  • Modified release tablet of bupropion hydrochloride
    Patent number: 7537784
    Abstract: A modified-release tablet of bupropion hydrochloride comprising (i) a core comprising an effective amount of bupropion hydrochloride, a binder, a lubricant; and (ii) a control releasing coat surrounding said core; and (iii) a moisture barrier surrounding said control releasing coat, wherein the modified-release tablet is bioequivalent to Wellbutrin® or Zyban®/Wellbutrin®SR tablets.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: May 26, 2009
    Assignee: Biovail Laboratories International SRL
    Inventors: Werner Oberegger, Okponanabofa Eradiri, Fang Zhou, Paul Maes
  • CHRONOTHERAPEUTIC DILTIAZEM FORMULATIONS AND THE ADMINISTRATION THEREOF
    Publication number: 20090118256
    Abstract: A method of treating or preventing myocardial ischemia in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of diltiazem in the blood at between about 10 hours and about 17 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to t
    Type: Application
    Filed: December 7, 2007
    Publication date: May 7, 2009
    Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.
    Inventors: Kenneth Stephen ALBERT, Theophilus Jones Gana, Paul Maes
  • BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS
    Publication number: 20080274181
    Abstract: Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.
    Type: Application
    Filed: October 31, 2007
    Publication date: November 6, 2008
    Applicant: BIOAVAIL LABORATORIES INTERNATIONAL S.R.L.
    Inventors: Paul Maes, Werner Oberegger, Mohammad Ashty Saleh